Last updated: September 27, 2026
Bromfenac ophthalmic solution is a mature topical NSAID market with established demand in postoperative cataract care. The main commercial opportunities are differentiated delivery systems, preservative-free presentations, low-irritation excipient systems, multi-dose packaging, and cost-efficient generic manufacturing. Prolensa 0.07%, BromSite 0.075%, Bromday 0.09%, and generic bromfenac products define the competitive field. The strongest product strategy is unlikely to rely on bromfenac itself, which is an established active ingredient, but on formulation performance, tolerability, packaging, manufacturing controls, and regulatory positioning.
What is bromfenac ophthalmic solution used for?
Bromfenac is a topical ophthalmic nonsteroidal anti-inflammatory drug used primarily to treat ocular inflammation and pain associated with cataract surgery. U.S. products include:
| Product |
Strength |
Primary sponsor or marketer |
Typical use |
| Prolensa |
0.07% bromfenac ophthalmic solution |
Bausch + Lomb |
Postoperative inflammation and pain after cataract surgery |
| BromSite |
0.075% bromfenac ophthalmic solution |
Sun Pharmaceutical Industries |
Postoperative inflammation and pain after cataract surgery |
| Bromday |
0.09% bromfenac ophthalmic solution |
Formerly Ista Pharmaceuticals; later Bausch + Lomb assets |
Postoperative inflammation after cataract surgery |
| Generic bromfenac ophthalmic solution |
Commonly 0.09% |
Multiple generic manufacturers |
Reference-product equivalent treatment |
The U.S. Food and Drug Administration approved Bromday in 2009, Prolensa in 2013, and BromSite in 2016. Product-specific indications and labeling differ, particularly regarding dosing frequency and postoperative use. FDA labels remain the controlling source for approved indications, inactive ingredients, warnings, and administration instructions (FDA, 2009, 2013, 2016).
What excipients are used in bromfenac ophthalmic solution?
Commercial bromfenac solutions use relatively conventional ophthalmic excipients. The formulation objectives are solubilization, pH control, tonicity, viscosity management, chelation, preservation, and chemical stability.
| Excipient class |
Common examples in bromfenac products |
Formulation function |
| Buffering agents |
Boric acid, sodium borate |
Maintain ophthalmic pH and control irritation |
| pH adjusters |
Sodium hydroxide |
Adjust final pH and support drug solubility |
| Chelating agents |
Edetate disodium |
Bind trace metals and reduce oxidation pathways |
| Wetting or viscosity agents |
Povidone; product-specific polymer systems |
Improve spreading, residence time, and drop delivery |
| Surfactants or solubilizers |
Polysorbate 80 in some formulations |
Improve wetting and formulation uniformity |
| Preservatives |
Benzalkonium chloride in some multidose products |
Control microbial growth after opening |
| Vehicle |
Purified water |
Continuous aqueous phase |
Prolensa contains bromfenac sodium equivalent to 0.07% bromfenac and uses boric acid, edetate disodium, povidone, polysorbate 80, sodium borate, sodium hydroxide, and water. BromSite contains bromfenac sodium equivalent to 0.075% bromfenac and uses a formulation system that includes boric acid, benzalkonium chloride, edetate disodium, povidone, sodium borate, sodium hydroxide, and water, according to its FDA prescribing information (Bausch + Lomb, 2023; Sun Pharmaceutical Industries, 2023).
The excipient list is commercially important because many development risks arise from interactions among bromfenac, preservatives, polymers, container materials, and trace metals rather than from the active ingredient alone.
What excipient strategy is strongest for a new bromfenac product?
A differentiated strategy should target one or more of five attributes: ocular tolerability, residence time, preservative reduction, stability, or manufacturing cost.
Preservative-free unit-dose formulation
A preservative-free bromfenac product could address concerns associated with repeated exposure to benzalkonium chloride, particularly in patients with ocular-surface disease, dry eye, or prolonged postoperative treatment. Unit-dose ampoules or blow-fill-seal containers would remove the need for an antimicrobial preservative after opening.
The tradeoffs are higher packaging cost, more complex filling operations, greater container-volume requirements, and increased risk of waste when a single dose is not fully used. A preservative-free formulation is most commercially attractive if it can demonstrate equivalent clinical performance while improving ocular-surface tolerability or supporting premium reimbursement.
Low-preservative multidose system
A multidose container with a validated microbiological barrier could reduce or eliminate benzalkonium chloride while retaining the convenience of a bottle. This approach requires substantial container-closure and in-use microbiological data. The commercial advantage is lower cost than unit-dose packaging and easier adoption by ophthalmology practices.
Potential technologies include one-way valves, airless pumps, antimicrobial bottle components, and mechanically protected dispensing systems. The device may create a separate patent position from the drug formulation.
Mucoadhesive or residence-time-enhancing vehicle
A viscosity-enhancing excipient can increase precorneal residence time and reduce rapid drainage through the nasolacrimal system. Povidone, hydroxypropyl methylcellulose, carboxymethylcellulose, hyaluronic acid, and selected poloxamers are potential candidates, subject to compatibility and regulatory precedent.
The target is not maximum viscosity. Excessive viscosity can cause blurred vision, transient discomfort, inconsistent drop formation, and poor patient acceptance. A practical formulation should preserve rapid spreading and optical clarity while improving retention.
Surfactant and solubilization platform
Bromfenac has limited aqueous solubility characteristics that require control of pH, salt form, and formulation environment. Surfactants such as polysorbates can improve wetting and physical uniformity, but they may introduce oxidation, peroxide, adsorption, or extractables concerns.
A new formulation may use a lower-surfactant system, alternative solubilization technology, or a different bromfenac salt or complex. The formulation must preserve chemical stability and avoid precipitation during storage, shipping, temperature cycling, and repeated dispensing.
Excipient system designed for manufacturing robustness
A lower-cost generic or follow-on product should prioritize reproducibility. The formulation should minimize sensitivity to:
- Raw-material variability
- Mixing order
- Dissolution temperature
- pH adjustment
- Filter adsorption
- Hold time before filling
- Container interaction
- Preservative concentration drift
A simpler formulation with fewer excipients may offer better manufacturing economics than a technically sophisticated vehicle. The commercial value depends on whether the simplified product remains pharmaceutically equivalent and clinically acceptable.
What formulations are protected by bromfenac patents?
Patent protection for bromfenac ophthalmic products has historically covered more than the active ingredient. Relevant claim categories include:
- Bromfenac compositions at defined concentrations.
- Ophthalmic solutions with specified pH ranges.
- Salt forms or stabilized bromfenac preparations.
- Reduced-dose or once-daily administration regimens.
- Viscosity-enhancing or residence-time-improving vehicles.
- Treatment of postoperative ocular inflammation.
- Combination or sequential treatment with other ophthalmic agents.
- Container-closure systems and dispensing devices.
- Manufacturing processes and sterile filling methods.
The strongest formulation patents generally require a specific combination of active concentration, excipient identity, pH, viscosity, dosing schedule, or clinical result. Broad claims directed only to bromfenac ophthalmic use are more exposed to prior-art and obviousness challenges because bromfenac has been marketed for many years.
A company evaluating freedom to operate should review issued claims, terminal disclaimers, patent-term adjustments, reexamination history, continuation applications, and the Orange Book listing for each reference product. A formulation that uses the same excipient combination as a branded product may create risk even if the active concentration differs.
What is the Orange Book status of bromfenac ophthalmic solution?
FDA’s Orange Book identifies patents and regulatory exclusivity associated with approved reference-listed drugs. Orange Book analysis should be conducted separately for Prolensa, BromSite, and any other listed reference product because each may have a different NDA, patent set, and regulatory history.
For a generic applicant, the main questions are:
- Which bromfenac product is the reference listed drug?
- What patents are currently listed for that NDA?
- Which patents expire before or after the target ANDA submission?
- Are the claims composition, method-of-use, or device-related?
- Can the applicant submit a Paragraph IV certification?
- Does the reference product have an unexpired method-of-use patent that can be carved out?
- Is pediatric or other regulatory exclusivity active?
A generic applicant may use Paragraph III certifications for patents that remain valid but have not expired, or Paragraph IV certifications when asserting that listed patents are invalid, unenforceable, or will not be infringed. A skinny-label strategy may be available for patented indications that can be omitted from the proposed labeling, provided the remaining label is legally and medically supportable under the ANDA framework (FDA, 2024a).
Because Orange Book listings and patent status can change through litigation, delisting, expiration, or administrative correction, a transaction or launch decision should use the current FDA Orange Book record and USPTO prosecution data.
When does bromfenac ophthalmic solution lose exclusivity?
Bromfenac does not have a single market-wide exclusivity date. Exclusivity depends on the specific product, NDA, patent family, and dosage regimen.
The practical market timeline is:
| Exclusivity layer |
Commercial relevance |
| Active-ingredient patents |
Generally limited for a mature drug such as bromfenac |
| Formulation patents |
May delay or shape generic entry |
| Method-of-use patents |
May require a label carve-out or Paragraph IV challenge |
| Device patents |
May affect branded delivery systems but often do not block all solution products |
| Regulatory exclusivity |
May restrict ANDA approval for a defined period |
| Patent litigation |
Can trigger a 30-month stay after a timely Paragraph IV notice |
| ANDA approval |
Does not always equal immediate commercial launch if litigation or settlement restrictions remain |
The highest-value remaining protection, where present, is usually tied to formulation, dosing, or delivery technology rather than bromfenac’s chemical identity.
Which companies are challenging bromfenac ophthalmic products?
Generic ophthalmic manufacturers have entered or pursued bromfenac markets through ANDA pathways. The competitive group has included established generic and ophthalmic specialists such as Akorn, Apotex, Teva, Dr. Reddy’s Laboratories, Sandoz, and other FDA-approved manufacturers, depending on product strength and reference listing.
Competition is constrained by ophthalmic manufacturing requirements. FDA approval requires evidence of sterility, particulate control, container-closure integrity, extractables and leachables assessment, stability, preservative effectiveness where applicable, and pharmaceutical equivalence. These requirements create higher barriers than those for many oral solid products.
The commercial threat differs by strength:
- A 0.09% generic may compete directly with Bromday-type products.
- A 0.07% generic must address the Prolensa reference product and its formulation and labeling requirements.
- A 0.075% product may compete with BromSite but may face more complex vehicle and delivery expectations.
- A preservative-free product can compete on tolerability and packaging rather than price alone.
What patent litigation and settlement issues affect bromfenac?
Bromfenac litigation risk is concentrated in three areas:
- Paragraph IV challenges against listed formulation or method-of-use patents.
- Disputes over whether a generic product practices a branded excipient or delivery claim.
- Settlement agreements that specify delayed entry, authorized generic rights, or restrictions on commercial launch.
A settlement can produce an entry date that differs from the nominal patent expiration date. It can also include provisions affecting supply, launch sequencing, or the scope of a generic label. Any diligence review should examine district court complaints, claim-construction rulings, Federal Circuit decisions, settlement filings, and the FDA litigation-status record.
A competitor with a simple bromfenac solution may avoid claims directed to a proprietary vehicle. A competitor using the same polymer, preservative concentration, or dosing regimen may face higher infringement exposure.
What are the commercial opportunities for bromfenac ophthalmic solution?
Premium preservative-free product
The most direct branded opportunity is a preservative-free product for patients with dry eye, corneal-surface disease, contact-lens-related sensitivity, or repeated postoperative dosing. Commercial success depends on clinical evidence showing tolerability or adherence benefits that justify a price premium.
Lower-cost generic platform
A manufacturer can pursue a cost-efficient product using established excipients and conventional sterile aqueous processing. The value proposition is reliable supply, competitive pricing, and pharmacy substitution. Margins will be exposed to price erosion if multiple ANDA holders launch simultaneously.
Combination postoperative regimen
A fixed combination with an antibiotic, corticosteroid, or intraocular-pressure therapy could simplify cataract postoperative treatment. Such a product would face formulation compatibility, preservative, stability, and regulatory risks. It may also create additional patent opportunities around dosing and sequential use.
International development
Bromfenac opportunity exists in markets where cataract surgery volumes are increasing and branded ophthalmic NSAIDs remain highly priced. Geographic strategy should account for local reference products, patent registers, bioequivalence standards, preservative restrictions, and public reimbursement.
Contract manufacturing and licensing
A company with sterile ophthalmic capacity can license:
- A differentiated bromfenac formulation
- A preservative-free packaging system
- A residence-time-enhancing vehicle
- A validated multidose bottle
- A regional marketing authorization
- A manufacturing process with improved yield or fill accuracy
The most defensible licensing asset is usually a combined formulation-and-device package supported by stability, in-use, and clinical or comparative-performance data.
How strong is the bromfenac patent estate?
The estate is strongest where claims are narrow, technically specific, and supported by comparative data. Examples include a defined bromfenac concentration with a particular excipient combination, a validated delivery system, or a clinically meaningful reduction in dosing frequency.
The estate is weaker where claims broadly cover topical bromfenac use without a distinctive formulation or treatment limitation. Prior art includes earlier ophthalmic NSAID products, bromfenac formulations, pharmaceutical salts, buffered aqueous solutions, and standard preservative systems.
A practical strength assessment should score each patent on:
| Factor |
Strong position |
Weak position |
| Claim scope |
Covers formulation and use |
Covers only broad use |
| Differentiation |
Requires non-obvious vehicle or device |
Uses routine excipients |
| Evidence |
Comparative clinical or stability data |
Limited supporting examples |
| Remaining term |
Multiple years of enforceable life |
Near expiration |
| Design-around risk |
Difficult to substitute excipients or change pH |
Easy to alter concentration or vehicle |
| Regulatory linkage |
Listed for the reference product |
Not listed or not relevant to approval |
What generic launch risks exist for bromfenac ophthalmic solution?
A generic launch may face five primary risks:
- Patent litigation following a Paragraph IV certification.
- Failure to demonstrate pharmaceutical equivalence or bioequivalence.
- Preservative effectiveness failure in a multidose package.
- Stability failure caused by oxidation, precipitation, or container interaction.
- Rapid price erosion after multiple generic approvals.
Ophthalmic products also face manufacturing risks involving sterile filtration, aseptic filling, particulate contamination, drop-size variability, and closure integrity. These issues can delay approval or trigger post-approval supply problems.
Key Takeaways
- Bromfenac ophthalmic solution is a mature postoperative NSAID market with established branded and generic products.
- The principal commercial differentiation opportunity is formulation and delivery technology, not the active ingredient.
- Preservative-free unit-dose products and low-preservative multidose systems have the clearest premium positioning.
- Povidone, borate buffers, edetate disodium, surfactants, and preservatives must be selected as an integrated system.
- Formulation, method-of-use, and device patents may remain relevant even where basic bromfenac protection has expired.
- Generic applicants should evaluate each reference product separately under the Orange Book and Paragraph IV framework.
- Sterile manufacturing capability, container technology, and stability data are important entry barriers.
- The most defensible licensing asset is a differentiated vehicle combined with packaging and supporting performance data.
FAQs
Is bromfenac ophthalmic solution preservative-free?
Not all bromfenac products are preservative-free. Some multidose products contain benzalkonium chloride, while other formulations may use different packaging or preservation strategies. The FDA-approved product label controls the inactive-ingredient profile.
Can bromfenac ophthalmic solution be reformulated with carboxymethylcellulose?
Yes, carboxymethylcellulose can be evaluated as a viscosity-enhancing or mucoadhesive excipient, but the formulation must meet requirements for clarity, sterility, drop delivery, tolerability, stability, and pharmaceutical equivalence.
Is Prolensa stronger than generic bromfenac 0.09%?
Strength alone does not establish superior clinical performance. Prolensa contains 0.07% bromfenac, while many generic products contain 0.09%. Differences in concentration, dosing frequency, vehicle, labeling, and reference product status must be assessed together.
Does a bromfenac formulation patent automatically block a generic launch?
No. The effect depends on the patent claims, the generic formulation, the proposed labeling, patent listing status, certification, litigation outcome, and any settlement agreement. A generic may design around the claims or carve out a patented method of use.
What is the most attractive new product concept in bromfenac ophthalmology?
A preservative-free, low-irritation, multidose bromfenac solution with validated microbial protection and improved ocular residence time has the strongest commercial rationale. Its value would depend on demonstrable tolerability, reliable dispensing, manufacturing cost, and regulatory differentiation.
References
-
Bausch + Lomb. (2023). Prolensa (bromfenac ophthalmic solution) prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2009). Bromday (bromfenac ophthalmic solution) approval package and prescribing information. FDA.
-
U.S. Food and Drug Administration. (2013). Prolensa (bromfenac ophthalmic solution) approval package. FDA.
-
U.S. Food and Drug Administration. (2016). BromSite (bromfenac ophthalmic solution) approval package and prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Sun Pharmaceutical Industries, Inc. (2023). BromSite (bromfenac ophthalmic solution) prescribing information. U.S. Food and Drug Administration.
